Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Amylyx Pharmaceuticals Inc before investing.

In this article, we go over a few key elements for understanding Amylyx Pharmaceuticals Inc’s stock price such as:

• Amylyx Pharmaceuticals Inc’s current stock price and volume
• Why Amylyx Pharmaceuticals Inc’s stock price changed recently
• Upgrades and downgrades for AMLX from analysts
• AMLX’s stock price momentum as measured by its relative strength

About Amylyx Pharmaceuticals Inc (AMLX)

Before we jump into Amylyx Pharmaceuticals Inc’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Amylyx Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery and development of treatments for neurodegenerative diseases. The Company is focused on the development and commercialization of its product candidate, AMX003 (sodium phenylbutyrate and taurursodiol, also known as ursodoxicoltaurine) for the treatment of amyotrophic lateral sclerosis (ALS). The Company is developing AMX0035 for other neurodegenerative diseases by leveraging knowledge and relationships in the neurodegenerative space. AMX0035 is a dual unfolded protein response (UPR)-Bax apoptosis inhibitor composed of PB and TURSO (also known as TUDCA). Its development of antisense oligonucleotides (ASOs), including lead ASO AMX0114, which targets calpain-2 (CAPN2), a gene encoding calcium-dependent proteolytic enzyme which has been implicated in the pathogenesis of ALS and other neurodegenerative diseases.

Want to learn more about Amylyx Pharmaceuticals Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Amylyx Pharmaceuticals Inc.

Amylyx Pharmaceuticals Inc’s Stock Price as of Market Close

As of January 25, 2024, 4:00 PM, CST, Amylyx Pharmaceuticals Inc’s stock price was $15.37.

Amylyx Pharmaceuticals Inc is up 6.96% from its previous closing price of $14.37.

During the last market session, Amylyx Pharmaceuticals Inc’s stock traded between $14.35 and $14.77. Currently, there are 67.41 million shares of Amylyx Pharmaceuticals Inc stock available for purchase.

Unfortunately, Amylyx Pharmaceuticals Inc’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.

Amylyx Pharmaceuticals Inc Stock Price History

Amylyx Pharmaceuticals Inc’s (AMLX) price is currently up 4.42% so far this month.

During the month of January, Amylyx Pharmaceuticals Inc’s stock price has reached a high of $17.06 and a low of $14.35.

Over the last year, Amylyx Pharmaceuticals Inc has hit prices as high as $41.93 and as low as $11.82. Year to date, Amylyx Pharmaceuticals Inc’s stock is down 58.4%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Amylyx Pharmaceuticals Inc Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of January 24, 2024, there was 1 analyst who downgraded Amylyx Pharmaceuticals Inc’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Amylyx Pharmaceuticals Inc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Amylyx Pharmaceuticals Inc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Amylyx Pharmaceuticals Inc’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Amylyx Pharmaceuticals Inc (AMLX) by visiting AAII Stock Evaluator.

Relative Price Strength of Amylyx Pharmaceuticals Inc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of January 24, 2024, Amylyx Pharmaceuticals Inc has a weighted four-quarter relative price strength of -26.28%, which translates to a Momentum Score of 13 and is considered to be Very Weak.

Want to learn more about how Amylyx Pharmaceuticals Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Amylyx Pharmaceuticals Inc Stock Price: Bottom Line

As of January 25, 2024, Amylyx Pharmaceuticals Inc’s stock price is $15.37, which is up 6.96% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Amylyx Pharmaceuticals Inc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.